Skip to main content

SINTESIS DE COMPUESTOS CON MECANISMOS INNOVADORES CONTRA ENFERMEDADES NEURODEGENERATIVAS Y DOLOR NEUROPATICO

PID2020-118127RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

A new family of subnanomolar inhibitors of soluble epoxide hydrolase

  • Escolano, Carmen
  • Bagán, Andrea
  • Turcu, Andreea L.
  • Morisseau, Christophe
  • Loza, María Isabel
  • Brea, José Manuel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Vázquez, Santiago
Trabajo presentado en el ASPET Annual Meeting at Experimental Biology 2022, celebrado en Philadelphia, PA (Estados Unidos), del 2 al 5 de abril de 2022, Epoxyeicosatrienoic acids (EETs) are endogenous chemical mediators derived from arachidonic acid that show anti-inflammatory, antihypertensive, analgesic, angiogenic, and antiatherosclerotic effects. Soluble epoxide hydrolase (sEH) converts EETs to the corresponding dihydroxyeicosatrienoic acids (DHETs), whereby the biological effects of EETs are diminished, eliminated, or altered.1 Therefore, inhibition of sEH has been suggested as a novel pharmacological approach for the treatment of pain-related disorders and various inflammatory diseases, and a few sEH inhibitors (sEHI) have reached clinical trials, This research was funded by Grants PID2020-118127RB-I00 and PID2019-107991RB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and by “ERDF A way of making Europe” to S.V. and C.E. Financial support from Generalitat de Catalunya (2017 SGR106) and Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), to S.V., and from the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. are acknowledged. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01DK103616 to B.D.H.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Soluble epoxide hydrolase inhibitors counteract microglia phenotypic changes induced by monomeric C-reactive protein: New perspectives against neuroinflammation in Alzheimer's disease

  • Yuan, Yi
  • Bartra Cabré, Clara
  • Valdes Quiroz, Haydée
  • Martín-López, Juan
  • Mullins, Joseph J.
  • Martínez, Noemí
  • Codony, Sandra
  • García-Lara, Elisa
  • Sawkulycz, Xenia
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
  • Slevin, Mark
  • Sanfeliu, Coral
Resumen del trabajo presentado en el XII Simposi de Neurobiologia, Societat Catalana de Biologia, celebrado en Barcelona (España), los días 7 y 8 de junio de 2022, Alzheimer's disease (AD) is the most prevalent neurodegenerative disease worldwide. Neuroinflammation is a crucial neuropathological trait in AD, although the underlying mechanisms are not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of blood CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology in experimental models. Here we analysed the phenotypic changes induced by mCRP in microglia, the main effector cells of the inflammatory response. Then we tested the protective action of inhibiting the soluble epoxide hydrolase enzyme (sEH), a promising druggable target in AD. sEH inhibitors (sEHi) increase intracellular levels of anti-inflammatory epoxyeicosatrienoic acids (EETs). BV2 microglial cells were incubated with 50 or 100 µM mCRP for 24 h. Leading molecules of chemical families of newly synthesized sEHi (UB-JML-99 and UB-JM-39) were used for protective assays. mCRP activated the nitric oxide pathway as shown by increased release of nitric oxide and higher gene expression of iNOS, whereas sEHi agents blocked these effects. mCRP increased the release of TNF¿ into the media and the expression of pro-inflammatory cytokines and chemokines. Furthermore, mCRP modified the epigenetic microglial phenotype suggesting a dysregulated pattern. sEHi generally inhibited damaging effects of mCRP with a higher potency than the standard compound TPPU. Overall we demonstrated that mCRP directly activates microglia inflammatory pathways and may contribute to the triggering and progression of AD. Moreover, sEHi were confirmed as effective therapeutic molecules against neuroinflammation in an AD scenario., Agencia Estatal de Investigación (España); Ministerio de Ciencia, Innovación y Universidades (España); Generalitat de Catalunya
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Soluble epoxide hydrolase inhibitors: design, synthesis, in vitro profiling and in vivo evaluation in murine models of pain

  • Vázquez, Santiago
  • Codony, Sandra
  • Entrena, José M.
  • Jora, Beatrice
  • González-Cano, Rafael
  • Loza, María Isabel
  • Brea, José Manuel
  • Morisseau, Christophe
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Cobos, Enrique J.
Trabajo presentado en el ASPET Annual Meeting at Experimental Biology 2022, celebrado en Philadelphia, PA (Estados Unidos), del 2 al 5 de abril de 2022, This research by the Grant PID2020-118127RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to S.V. Financial support from Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), to S.V., and from the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. are acknowledged. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

A new family of soluble epoxide hydrolase inhibitors: in vivo evaluation in a murine model of chemotherapy-induced neuropathic pain

  • Vázquez, Santiago
  • Codony, Sandra
  • Jora, Beatrice
  • Turcu, Andreea L.
  • Calvó-Tusell, Carla
  • Morisseau, Christophe
  • Loza, María Isabel
  • Brea, José Manuel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Pérez, Belén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Hammock, Bruce D.
  • Osuna, Sílvia
  • Feixas, Ferran
  • Cobos, Enrique J.
Trabajo presentado en el 22nd European Symposium on Organic Chemistry, celebrado en Ghent (Bélgica), del 9 al 13 de julio de 2023, Thisworkwasfundedbythethe Grant PID2020-118127RB-I00 fundedbyMCIN/AEI/10.13039/501100011033andby“ERDFAwayofmakingEurope”toS.V.,andthe Xunta de Galicia (ED431G2019/02andED431C2018/21).PartialsupportwasprovidedbyNIH-NIEHSRiverAwardR35ES03443,NIH-NIEHSSuperfundProgramP42ES004699,NINDSR01DK107767,andNIDDKR01DK103616toB.D.H.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

High levels of anti-inflammatory epoxyeicosatrienoic acids may improve neurodevelopment in children prenatally exposed to mercury

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Llop, Sabrina
  • Kuligowski, Julia
  • Albiach-Delgado, Abel
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
  • Ballester, Ferrán
  • Soler-Blasco, Raquel
  • Jora, Beatrice
  • Jarné-Ferrer, Júlia
  • Griñán-Ferré, Christian
  • Vázquez, Santiago
  • Pallàs, Mercè
Trabajo presentado en Neuroscience 2023, celebrado en Washington D. C. (Estados Unidos), del 11 al 15 de noviembre de 2023, A balanced concentration of polyunsaturated fatty acids (PUFA) in the prenatal stage is essential for children¿s neurodevelopment. Also, animal studies showed that high levels of anti-inflammatory PUFA metabolites in the embryonic brain protect against genetic or environmental insults that would otherwise cause cognitive impairment. Here we used liquid chromatography - mass spectrometry to analyze oxylipins, the oxygenated metabolites of PUFA, in the placenta tissue (N=12) and cord blood plasma (N=39) of children from the INMA cohort (Valencia, Spain). Both tissues were characterized for total Hg levels as a reference for developmental neurotoxic MeHg exposure during pregnancy and distributed in low and high Hg groups. Deleterious effects of high Hg were confirmed in the placenta as decreased proteasome activity and inhibitory epigenetic changes. Children¿s neurodevelopment was assessed using the Bayley (14 months) and McCarthy (5 years) scales. Spearman correlation coefficients were calculated between scores and oxylipin levels. We also analyzed cortical brain tissue from wild type and transgenic Alzheimer's disease (5XFAD) mice dosed for 2 months with vehicle or a soluble epoxide hydrolase enzyme (sEH) inhibitor, UB-BJ-02 (5 mg/Kg, N=5/group). Inhibition of sEH increases levels of the potent anti-inflammatory epoxyeicosatrienoic acids (EETs) by inhibiting their hydrolysis to dihydro-EETs (DiHETs). We found that DiHETs were increased in the placenta of high Hg group. Furthermore, the mental and psychomotor development of 14-month-old children correlates positively with DiHETs levels in both placenta and cord blood tissues. Interestingly, cord blood DiEHTs positively correlate with working memory at 5 years. Thus we suggest that higher levels of DiHETs indicate higher synthesis of their anti-inflammatory EETs precursors. Accordingly, placenta levels of EETs correlate with mental development at 14 months of age. Other oxylipin changes also suggested an involvement of inflammatory mechanisms in the neurodevelopment of children exposed to MeHg. In general, higher levels of markers of resolved inflammation or final stable metabolites in the placenta and cord blood tissues correlate with better neuropsychological development in children exposed to environmental MeHg. Finally, mouse treatment with the drug UB-BJ-02 showed increased EETs and decreased pro-inflammatory markers in brain tissue. Both human and experimental results showed that EETs are prominent anti-inflammatory metabolites and support sEH inhibition as an anti-inflammatory treatment to increase brain resilience to environmental risk of neurodevelopmental damage., Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB and PDC2021-121096); European Union “NextGenerationEU”/PRTR; CERCA program/Generalitat de Catalunya; 2021-SGR-357 from AGAUR; H2020 874583; FIS/FEDER 19/1338; 16/1288; AICO/2020/285; CIAICO/2021/132; MS20/0006; MS21/0133
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Soluble epoxide hydrolase inhibitors counteract microglia pro-inflammatory response induced by monomeric C-reactive protein

  • Bartra Cabré, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Valdés-Quiroz, Haydeé
  • Codony, Sandra
  • Sawkulycz, Xenia
  • Slevin, Mark
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Trabajo presentado en el 36th ECNP Congress, celebrado en Barcelona (España), del 7 al 10 de octubre de 2023, Neuroinflammation is a crucial neuropathological trait in Alzheimer’s disease (AD), although its role in the development of AD is not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of circulating CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology when injected into mouse hippocampus [1]. Furthermore, treatment of pregnant mice with TPPU, an inhibitor of the soluble epoxide hydrolase enzyme (sEH) with anti-inflammatory properties, successfully prevented memory loss and AD pathology in the offspring by inducing long-term modifications in the epigenetic machinery [2]., Funding: Spanish Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB-I00 and PDC2021-121096); CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

New dual sEH-AChE inhibitors with amyloid antiaggreganting actiivy fo the treatment of Alzheimer's disease

  • Sampietro, Anna
  • Haberek, Wawrzyniec
  • Bellver, Aina
  • Griñán-Ferré, Christian
  • Pérez, Belén
  • Pérez de la Lastra Aranda, Carmen
  • Palomo, Valle
  • Naldi, Marina
  • Bartolini, Manuela
  • Loza, María Isabel
  • Brea, José Manuel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Morisseau, Christophe
  • Sabaté, Raimon
  • Hammock, Bruce D.
  • Pallàs, Mercè
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
Resumen del trabajo presentado en el 4th Molecules Medicinal Chemistry Symposium, celebrado en Barcelona del 24 al 26 de abril de 2024
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Overcoming Pain Management: Unlocking the Power of Dual-Mechanism Compounds

  • Escriche, Celia
  • Sánchez, Javier
  • Pujol, Eugènia
  • Martínez-López, juan
  • Brea, José Manuel
  • Morisseau, Christophe
  • Pérez, Belén
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Loza, María Isabel
  • Vázquez, Santiago
Trabajo presentado en el 4th Molecules Medicinal Chemistry Symposium: Harnessing the Power of New Drug Modalities, celebrado en Barcelona del 24 al 26 de abril de 2024, This work was funded by the Grants PID2020-118127RB-I00, to S.V., and PID2021-121096-C22, to C.S., funded by MICIU/AEI/10.13039/501100011033 and by “European Union NextGenerationEU/PRTR”, and the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. C.E.M. and J.S. thank the Spanish MICIU for PhD Grants (FPI program). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

N-substituted piperidines in benzohomoadamantane-based ureas: potent inhibitors of soluble epoxide hydrolase with anti-inflammatory activity

  • López-Ruiz, Alba
  • Codony, Sandra
  • Jora, Beatrice
  • Turcu, Andreea L.
  • Morisseau, Christophe
  • Loza, María Isabel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Vázquez, Santiago
Trabajo presentado en el 4th Molecules Medicinal Chemistry Symposium: Harnessing the Power of New Drug Modalities, celebrado en Barcelona del 24 al 26 de abril de 2024, This work was funded by the Grant PID2020-118127RB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to S.V., and the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. A.L.R. thanks the Spanish MICIU for a PhD Grant (FPI program). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Uncovering the amyloid anti-aggregation potential of novel dual sEH-AChE inhibitors for Alzheimer's disease treatment

  • Sampietro, Anna
  • Haberek, Wawrzyniec
  • Bellver, Aina
  • Griñán-Ferré, Christian
  • Pérez, Belén
  • Pérez de la Lastra Aranda, Carmen
  • Palomo, Valle
  • Naldi, Marina
  • Bartolini, Manuela
  • Loza, María Isabel
  • Brea, José Manuel
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Morisseau, Christophe
  • Sabaté, Raimon
  • Hammock, Bruce D.
  • Pallàs, Mercè
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
Resumen del trabajo presentado en el 14th Summer School on Medicines, celebrado en Ribeirão Preto, SP (Brasil), del 29 de junio al 5 de julio de 2024, Alzheimer's disease (AD) stands as the predominant cause of dementia globally, exhibiting a complex nature influenced by various underlying mechanisms that contribute to its onset and progression. In response to this complexity, there's a growing interest in multitarget drug design, aimed at addressing multiple disease mechanisms with a single compound. Among the myriad of implicated factors, three key players emerge: neuroinflammation, cholinergic deficit, and protein aggregation. To tackle these interconnected aspects, our approach involves: 1) combating neuroinflammation by inhibiting soluble epoxide hydrolase (sEH), thereby elevating the levels of its substrate, the anti-inflammatory epoxyeicosatrienoic acids (EETs); 2) elevating acetylcholine levels through acetylcholinesterase (AChE) inhibition to compensate the cholinergic deficit; and 3) interfering the spontaneous aggregation of amyloidogenic proteins, thereby pursuing a so far unexplored target combination profile. In our research, we present a novel class of inhibitors targeting both sEH and AChE that additionally possess amyloid anti-aggregating properties. These inhibitors were developed by linking sEH and AChE inhibitor pharmacophores through a suitable linker. The resulting hybrid compounds exhibit enhanced potency against sEH and AChE compared to standard inhibitors, having subnanomolar or single-digit nanomolar IC50 values. Moreover, they demonstrate significant inhibitory activity against beta-amyloid and tau aggregation, with inhibition rates surpassing 50% at a concentration of 10 M. Notably, some compounds do also inhibit the aggregation of TDP-43, a protein involved in various neurodegenerative disorders, including AD and amyotrophic lateral sclerosis (ALS). Furthermore, the majority of these compounds are nonneurotoxic in SH-SY5Y cells at concentrations up to 100 M, possess the ability to cross the bloodbrain barrier according to the PAMPA-BBB assay, and display moderate aqueous solubility and microsomal stability. Ongoing studies include pharmacokinetic evaluations and efficacy assessments in an AD mouse model using a lead compound, aiming to further elucidate its potential as a disease-modifying anti-AD drug candidate., This work was supported by grant PID2020-118127RB-I00 funded by MICIN/AEI/10.13039/501100011033 and 2021SGR00357 from AGAUR